Prothena Corporation PLC

PRTA

Equity

ISIN IE00B91XRN20 / Valor 20224443

NASDAQ (2025-03-13)

USD 14.07+1.52%

Prothena Corporation PLC
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

Prothena Corporation PLC is a biotechnology firm focused on the late-stage clinical development of treatments for neurodegenerative and rare peripheral amyloid diseases. Leveraging its expertise in protein dysregulation, the company has developed a diverse pipeline of investigational therapies aimed at addressing the complex challenges of neurological dysfunction and misfolded proteins. Prothena's approach combines internal discovery with strategic collaborations across academia and the industry to advance its portfolio of novel therapeutic solutions. Founded from the legacy of Athena Neurosciences and established as an independent entity in December 2012, Prothena trades on the Nasdaq Global Select Market under the symbol "PRTA." The company's commitment to innovation is rooted in its history of significant scientific contributions, including discoveries that have advanced the understanding of Alzheimer’s disease and the development of FDA-approved treatments for multiple sclerosis.

Summarized from source with an LLMView SourceSector: Technology

Net Loss

For the third quarter of 2024, Prothena Corporation PLC reported a net loss of $59.0 million, compared to a net income of $21.9 million in the same quarter of 2023. For the first nine months of 2024, the net loss was $64.4 million, compared to a net loss of $79.6 million for the same period in 2023. The net loss per share was $1.10 for the third quarter and $1.20 for the first nine months of 2024.

Revenue

Prothena Corporation PLC reported total revenue of $1.0 million for the third quarter of 2024, a significant decrease from $84.9 million in the third quarter of 2023. For the first nine months of 2024, total revenue was $133.0 million, compared to $91.1 million for the same period in 2023. The revenue was primarily derived from collaboration revenue with Bristol Myers Squibb.

Research and Development Expenses

Research and development expenses for Prothena Corporation PLC totaled $50.7 million for the third quarter of 2024, down from $57.9 million in the same quarter of 2023. For the first nine months of 2024, R&D expenses were $172.3 million, up from $158.7 million for the same period in 2023. The changes were primarily due to variations in manufacturing and clinical trial expenses.

General and Administrative Expenses

General and administrative expenses for Prothena Corporation PLC were $16.8 million for the third quarter of 2024, slightly up from $16.6 million in the third quarter of 2023. For the first nine months of 2024, G&A expenses were $50.4 million, compared to $44.9 million for the same period in 2023. The increase was mainly due to higher personnel-related expenses.

Cash Position

As of September 30, 2024, Prothena Corporation PLC had $520.1 million in cash, cash equivalents, and restricted cash, with no debt. The company expects to end the year with approximately $468 million in cash, cash equivalents, and restricted cash, based on its financial guidance for 2024.

Summarized from source with an LLMView Source

Key figures

-50.8%1Y

-57.9%3Y

40.7%5Y

Performance

70.6%1Y

76.2%3Y

77.9%5Y

Volatility